Heidelberg Pharma 過去の業績
過去 基準チェック /06
Heidelberg Pharmaの収益は年間平均-7.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間17% 10.3%割合で 減少しています。
主要情報
-7.62%
収益成長率
2.95%
EPS成長率
| Biotechs 業界の成長 | -14.59% |
| 収益成長率 | -10.27% |
| 株主資本利益率 | n/a |
| ネット・マージン | -444.62% |
| 前回の決算情報 | 31 May 2026 |
最近の業績更新
Recent updates
ナラティブ更新 • May 30
HPHA: Phase II Expansion Will Drive Future Upside Despite Going Concern Risks
Analysts now set a lower price target for Heidelberg Pharma, moving it from €6.75 to €5.50, as updated assumptions point to a very large future P/E multiple alongside tempered revenue growth expectations and a slimmer profit margin outlook. What's in the News Auditor Baker Tilly issued an unqualified opinion on the latest annual report but raised doubts about Heidelberg Pharma's ability to continue as a going concern, flagging liquidity and financing as key risk areas (Annual filing, period ending 30 Nov 2025).ナラティブ更新 • May 11
HPHA: Phase II Expansion And China Milestone Will Support Future Upside
Analysts have maintained their €6.75 price target for Heidelberg Pharma, citing slightly adjusted model assumptions regarding the discount rate, revenue growth and future P/E to reflect updated expectations, while keeping their overall valuation view unchanged. What's in the News Auditor Baker Tilly issued an unqualified opinion on Heidelberg Pharma's annual report for the period ending 30 November 2025, while expressing doubt about the company's ability to continue as a going concern.ナラティブ更新 • Apr 22
HPHA: Phase II Dose Selection And China Milestone Will Support Future Upside
Analysts have kept their €6.75 price target for Heidelberg Pharma unchanged, noting only minor adjustments in the discount rate and future P/E assumptions while maintaining their existing fair value view. What's in the News Heidelberg Pharma set the recommended Phase II dose for its lead candidate pamlectabart tismanitin (HDP-101) in a Phase I/IIa study for relapsed or refractory multiple myeloma, after a review found the drug was well tolerated at evaluated dose levels and a maximum tolerated dose was not reached (Product-Related Announcements).
新しいナラティブ • Apr 16
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Apr 08
HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have maintained their price target for Heidelberg Pharma at €6.75, citing updated assumptions that combine a very large projected revenue growth rate with an unchanged profit margin and a lower future P/E multiple. What's in the News Heidelberg Pharma plans to present preclinical data for its Amanitin-based ADC candidate HDP-103 for metastatic castration-resistant prostate cancer at the AACR Annual Meeting 2026 in San Diego, with a poster session scheduled on 21 April from 2:00 pm to 5:00 pm PDT (company announcement).
新しいナラティブ • Apr 01
Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential
Catalysts About Heidelberg Pharma Heidelberg Pharma is a biotechnology company focused on developing antibody drug conjugates based on its proprietary Amanitin payload technology. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Mar 24
HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have kept their €6.75 price target for Heidelberg Pharma broadly unchanged, citing only marginal shifts in inputs such as the discount rate, long term profit margin assumptions and future P/E, which together leave their overall valuation view effectively steady. What's in the News Huadong Medicine has reached a development milestone under its 2022 license agreement with Heidelberg Pharma, triggering a milestone payment to Heidelberg Pharma, with financial details not disclosed (company announcement).ナラティブ更新 • Mar 08
HPHA: Steady Assumptions And Undervalued Outlook Will Support Future Upside
Analysts are keeping their price target for Heidelberg Pharma steady at €6.75. They cite only marginal tweaks to their discount rate and long term assumptions for revenue growth, profit margin and future P/E, rather than any shift in their core view on the stock.ナラティブ更新 • Feb 21
HPHA: New Leadership And High Growth Assumptions Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions supporting this unchanged view. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer of Heidelberg Pharma AG, effective immediately (Key Developments).ナラティブ更新 • Feb 07
HPHA: Leadership Transition And Stable Outlook Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75. They point to only small shifts in inputs such as the discount rate and the assumed future P/E multiple as reasons for maintaining their existing view.ナラティブ更新 • Jan 24
HPHA: Positive Trial Data And New Leadership Will Support Future Upside
Analysts have revised their price target for Heidelberg Pharma from €10.56 to €6.75, citing updated assumptions for revenue growth, profit margins, discount rates, and future P/E that change their assessment of the company’s risk profile and earnings potential. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer and appointed Dr Dongzhou Jeffery Liu as the new CEO with immediate effect.
新しいナラティブ • Apr 13
ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers
Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings.分析記事 • Feb 16
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 05
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Heidelberg Pharma AG's ( ETR:HPHA ) price-to-sales (or "P/S") ratio of 15x might make it look like a strong sell right...分析記事 • Jul 21
Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Celebrations may be in order for Heidelberg Pharma AG ( ETR:HPHA ) shareholders, with the analysts delivering a...分析記事 • Oct 16
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Heidelberg Pharma AG ( ETR:HPHA ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Nov 28
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Mar 27
Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
The analysts covering Heidelberg Pharma AG ( ETR:HPHA ) delivered a dose of negativity to shareholders today, by making...分析記事 • Mar 15
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, Heidelberg Pharma...分析記事 • Jan 17
Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Heidelberg Pharma AG ( ETR:HPHA ) shareholders might be concerned after seeing the share price drop 14% in the last...収支内訳
収支内訳
Heidelberg Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 May 26 | 7 | -33 | 7 | 34 |
| 28 Feb 26 | 3 | -41 | 8 | 38 |
| 30 Nov 25 | 1 | -42 | 8 | 39 |
| 31 Aug 25 | 3 | -26 | 7 | 27 |
| 31 May 25 | 4 | -23 | 7 | 25 |
| 28 Feb 25 | 7 | -21 | 7 | 23 |
| 30 Nov 24 | 7 | -19 | 7 | 22 |
| 31 Aug 24 | 8 | -19 | 7 | 22 |
| 31 May 24 | 10 | -13 | 7 | 24 |
| 29 Feb 24 | 9 | -18 | 6 | 27 |
| 30 Nov 23 | 10 | -20 | 6 | 28 |
| 31 Aug 23 | 9 | -22 | 5 | 31 |
| 31 May 23 | 11 | -27 | 5 | 29 |
| 28 Feb 23 | 20 | -19 | 6 | 26 |
| 30 Nov 22 | 19 | -20 | 6 | 26 |
| 31 Aug 22 | 17 | -21 | 6 | 22 |
| 31 May 22 | 13 | -22 | 6 | 20 |
| 28 Feb 22 | 2 | -27 | 5 | 20 |
| 30 Nov 21 | 2 | -26 | 4 | 19 |
| 31 Aug 21 | 2 | -25 | 4 | 19 |
| 31 May 21 | 7 | -22 | 4 | 20 |
| 28 Feb 21 | 7 | -20 | 4 | 19 |
| 30 Nov 20 | 9 | -18 | 4 | 18 |
| 31 Aug 20 | 10 | -17 | 4 | 17 |
| 31 May 20 | 7 | -15 | 4 | 15 |
| 29 Feb 20 | 8 | -12 | 4 | 12 |
| 30 Nov 19 | 7 | -10 | 3 | 11 |
| 31 Aug 19 | 7 | -10 | 3 | 11 |
| 31 May 19 | 6 | -11 | 3 | 11 |
| 28 Feb 19 | 4 | -12 | 3 | 12 |
| 30 Nov 18 | 4 | -12 | 3 | 11 |
| 31 Aug 18 | 4 | -11 | 3 | 10 |
| 31 May 18 | 3 | -11 | 3 | 10 |
| 28 Feb 18 | 2 | -11 | 3 | 10 |
| 30 Nov 17 | 2 | -11 | 3 | 9 |
| 31 Aug 17 | 2 | -10 | 3 | 8 |
| 31 May 17 | 2 | -8 | 2 | 7 |
| 28 Feb 17 | 2 | -7 | 2 | 6 |
| 30 Nov 16 | 2 | -6 | 2 | 6 |
| 31 Aug 16 | 2 | -7 | 4 | 6 |
| 31 May 16 | 2 | -7 | 4 | 5 |
| 29 Feb 16 | 2 | -7 | 5 | 5 |
| 30 Nov 15 | 3 | -7 | 5 | 4 |
| 31 Aug 15 | 3 | -5 | 3 | 5 |
質の高い収益: HPHAは現在利益が出ていません。
利益率の向上: HPHAは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: HPHAは利益が出ておらず、過去 5 年間で損失は年間7.6%の割合で増加しています。
成長の加速: HPHAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: HPHAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 1.2% ) と比較することは困難です。
株主資本利益率
高いROE: HPHAの負債は資産を上回っているため、自己資本利益率を計算することは困難です。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/06 06:10 |
| 終値 | 2026/08/06 00:00 |
| 収益 | 2026/05/31 |
| 年間収益 | 2025/11/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Heidelberg Pharma AG 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Bruno Bulic | Baader Helvea Equity Research |
| Christian Weiz | Baader Helvea Equity Research |
| Robin Davison | Edison Investment Research |